Drug intelligence / Profile preview

ChronVac-B

Development stage: Discontinued
Lead developer: ChronTech Pharma
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

**ChronVac-B** is a therapeutic DNA vaccine developed by ChronTech Pharma for the treatment of chronic hepatitis B (CHB). It utilizes a plasmid DNA encoding the hepatitis B surface antigen (HBsAg) delivered via electroporation to induce robust T-cell and antibody responses aimed at achieving functional cure by reducing HBsAg levels and HBV DNA. The vaccine was evaluated in phase II clinical trials, often in combination with other antivirals like pegylated interferon, showing promising immunogenicity but development has been discontinued.

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on ChronVac-B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChronVac-B.

Explore the full profile